No Picture
Business News

Wall Street dips on trade woes, weak earnings

(Reuters) – U.S. stock indexes were down on Thursday, but off their session lows on what some traders said was due to technical buying amid worries of the outcome of U.S.-China trade talks, rising interest rates and disappointing earnings reports.

…read more […]

No Picture
Business News

Wall Street drops on trade woes, weak earnings

(Reuters) – Major U.S. indexes fell more than 1 percent in a broad slump on Thursday as investors remained wary about the outcome of U.S.-China trade talks and potential for rising interest rates, while a slew of disappointing earnings reports also weighed.

…read more […]

No Picture
Trading Ideas

As much as $600,000 in cash fell out of a truck on the highway — and police are asking people who took the money to return it or be charged with theft

Hundreds of thousands of dollars billowed out of the back of a Brinks armored truck on Interstate 70 in Indianapolis on Thursday. Drivers on Interstate 70 in Indianapolis, Indiana, were unexpectedly showered with hundreds of thousands of dollars after the back of a Brinks armored truck blew open on the interstate. “Bags of money were falling out of the back onto the interstate,” Indiana State Police Corporal Brock McCooe told Fox 8. …read more […]

No Picture
Trading Ideas

Giuliani offers new explanation of why Trump fired Comey

President Donald Trump’s explanation for why he fired FBI Director James Comey has shifted again. Rudy Giuliani, Trump’s new attorney, said in an interview on Fox News that Trump fired Comey last year because Comey would not state “that he wasn’t a target” of the special counsel’s Russia investigation. “He fired Comey because Comey would not, among other things, say that he wasn’t a target of the investigation,” Giuliani said. …read more […]

No Picture
Trading Ideas

Regeneron’s newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company’s future sales growth as its best-selling eye drug Eylea faces more competition. Regeneron is bracing for a hit to Eylea’s sales by focusing on expanding Dupixent’s label to reach more patients and venturing into the hot new field of immuno-oncology with a potential regulatory approval later this year. Just two days ago, Regeneron and partner Sanofi SA slashed the price on Praluent by more …read more […]